Application of humanized Anti-IgE antibodies (omalizumab) : AAAA new principle in the treatment of allergic diseases in ENT medicine;Die Anwendung von humanisierten Anti-Immunoglobulin-E-Antïkorpern : EEEin neues Therapieprinzip bei allergischen Erkrankungen in der HNO-Heilkunde

HNO

Volumn 55, Issue 12, 2007, Pages 981-992

  Pfaar, O ^a   Klimek, L ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allergic rhinoconjunctivitis; Anti IgE antibodies; Bronchial asthma; Omalizumab

Indexed keywords

ANTIALLERGIC AGENT; MONOCLONAL ANTIBODY; OMALIZUMAB;

ARTICLE; CLINICAL PRACTICE; EAR NOSE THROAT DISEASE; HUMAN; HYPERSENSITIVITY; OTORHINOLARYNGOLOGY;

ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; HYPERSENSITIVITY; OTOLARYNGOLOGY; OTORHINOLARYNGOLOGIC DISEASES; PHYSICIAN'S PRACTICE PATTERNS;

EID: 36749085268     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-007-1627-4     Document Type: Article

References (48)

1. Adelroth E, Rak S, Haahtela T et al. (2000) Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106: 253-259
2. Ayres JG, Higgins B, Chilvers ER et al. (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59: 701-708
3. BLA document BS10 (2007) Review of Clinical Safety Data.
4. Boulet LP, Chapman KR, Cote J et al. (1997) Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155: 1835-1840
5. Bousquet J, Van CP, Khaltaev N (2001) Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108: S147-S334
6. Buhl R, Hanf G, Soler M et al. (2002) The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 20: 1088-1094
7. Busse W, Corren J, Lanier BQ et al. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108: 184-190
8. Casale TB, Condemi J, LaForce C et al. (2001) Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 286: 2956-2967
9. Chervinsky P, Casale T, Townley R et al. (2003) Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 91: 160-167
10. Corren J, Casale T, Deniz Y, Ashby M (2003) Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 111: 87-90
11. Crystal-Peters J, Neslusan C, Crown WH, Torres A (2002) Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 109: 57-62
12. Deniz YM, Gupta N (2005) Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 29: 31-48
13. Enk AH, Katz SI (1992) Identification and induction of keratinocyte-derived IL-10. J Immunol 149: 92-95
14. Fahy JV, Fleming HE, Wong HH et al. (1997) The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155: 1828-1834
15. FDA Prescribing Information (2007) Xolair.
16. FDA Centers for Biologics Evaluation and Research, Pulmonary-Allergy Drugs Advisory Committee (2003) PADAC hearing transcripts.
17. Finn A, Gross G, Bavel J van et al. (2003) Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 111: 278-284
18. Global Initiative for Asthma (GINA) (1995) Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO workshop report (based on a March 1995 meeting). NIH Publication no 95-3659
19. Gordon J, Flores-Romo L, Cairns JA et al. (1989) CD23: a multi-functional receptor/lymphokine? Immunol Today 10: 153-157
20. Holgate S, Bousquet J, Wenzel S et al. (2001) Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 17: 233-240
21. Holgate ST, Chuchalin AG, Hebert J et al. (2004) Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34: 632-638
22. Humbert M, Beasley R, Ayres J et al. (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60: 309-316
23. Ishizaka K, Ishizaka T (1966) Physicochemical properties of reaginic antibody. 1. Association of reaginic activity with an immunoglobulin other than gammaA- or gammaG-globulin. J Allergy 37: 169-185
24. Ishizaka K, Ishizaka T, Hornbrook MM (1966) Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity wth gamma-E-globulin antibody. J Immunol 97: 840-853
25. Johansson SG (1967) Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 2: 951-953
26. Jones HE, Inouye JC, McGerity JL, Lewis CW (1975) Atopic disease and serum immunoglobulin-E. Br J Dermatol 92: 17-25
27. Juniper EF, Guyatt GH (1991) Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21: 77-83
28. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE (1993) Measuring quality of life in asthma. Am Rev Respir Dis 147: 832-838
29. Kay AB, Ying S, Varney V et al. (1991) Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 173: 775-778
30. Lemanske RF Jr, Nayak A, McAlary M et al. (2002) Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 110: e55
31. Lin H, Boesel KM, Griffith DT et al. (2004) Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 113: 297-302
32. MacGlashan D Jr, Kenzie-White J, Chichester K et al. (1998) In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody. Blood 91: 1633-1643
33. MacGlashan DW Jr, Bochner BS, Adelman DC et al. (1997) Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158: 1438-1445
34. Maggi E, Parronchi P, Manetti R et al. (1992) Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol 148: 2142-2147
35. Malveaux FJ, Conroy MC, Adkinson NF Jr, Lichtenstein LM (1978) IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest 62: 176-181
36. Maurer D, Ebner C, Reininger B et al. (1995) The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol 154: 6285-6290
37. Maurer D, Stingl G (1995) Immunoglobulin E-binding structures on antigen-presenting cells present in skin and blood. J Invest Dermatol 104: 707-710
38. Milgrom H, Berger W, Nayak A et al. (2001) Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108: E36
39. Milgrom H, Fick RB Jr, Su JQ et al. (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341: 1966-1973
40. Paramore C, Leidy N, Watrous M et al. (2000) Impact of disease severity and co-morbid allergic rhinitis on costs of care for patients with asthma. Am J Respir Crit Care Med 161: A789
41. Prussin C, Griffith DT, Boesel KM et al. (2003) Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 112: 1147-1154
42. Soler M, Matz J, Townley R et al. (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18: 254-261
43. Stingl G, Maurer D (1997) IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Int Arch Allergy Immunol 113: 24-29
44. Upham JW (2003) The role of dendritic cells in immune regulation and allergic airway inflammation. Respirology 8: 140-148
45. Van Reijsen FC, Bruijnzeel-Koomen CA, Kalthoff FS et al. (1992) Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 90: 184-193
46. Vercelli D (1993) Regulation of IgE synthesis. Allergy Proc 14: 413-416
47. Vignola AM, Humbert M, Bousquet J et al. (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59: 709-717
48. Yawn BP, Yunginger JW, Wollan PC et al. (1999) Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 103: 54-59